(NASDAQ: AMLX) Amylyx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Amylyx Pharmaceuticals's revenue in 2025 is -$1,272,000.On average, 1 Wall Street analysts forecast AMLX's revenue for 2026 to be $57,941,707, with the lowest AMLX revenue forecast at $57,941,707, and the highest AMLX revenue forecast at $57,941,707. On average, 2 Wall Street analysts forecast AMLX's revenue for 2027 to be $1,825,609,462, with the lowest AMLX revenue forecast at $1,128,526,161, and the highest AMLX revenue forecast at $2,522,692,762.
In 2028, AMLX is forecast to generate $6,169,900,337 in revenue, with the lowest revenue forecast at $3,942,710,278 and the highest revenue forecast at $8,397,090,395.